11a, 12-derivatives of tetracycline compounds
View Patent ↗11 a ,12-dehydrotetracycline compounds are described.
1. A pharmaceutical composition comprising a compound selected from the group consisting of
and a pharmaceutically acceptable carrier.
2. The pharmaceutical composition of claim 1 , wherein said compound is present in an amount effective to ameliorate a disease selected from: bacterial infection, multiple sclerosis, central pontine myelinolysis, leukodystrophy, acute disseminated encephalomyelitis, progressive multifocal leukoencephalopathy, and subacute sclerosing panencephalitis.
3. A method for ameliorating a disease selected from: bacterial infection, multiple sclerosis, central pontine myelinolysis, leukodystrophy, acute disseminated encephalomyelitis, progressive multifocal leukoencephalopathy, and subacute sclerosing panencephalitis in a subject in need thereof, comprising administering to said subject an effective amount of a compound of selected from the group consisting of the following compounds:
such that said disease is ameliorated.
4. The method of claim 3 , wherein said subject is a mammal.
5. The method of claim 3 , wherein said subject is a human.
6. The method of claim 3 , wherein said disease is bacterial infection.
7. The method of claim 3 , wherein said disease is central pontine myelinolysis.
8. The method of claim 3 , wherein said disease is leukodystrophy.
9. The method of claim 3 , wherein said disease is acute disseminated encephalomyelitis.
10. The method of claim 3 , wherein said disease is progressive multifocal leukoencephalopathy.
11. The method of claim 3 , wherein said disease is subacute sclerosing panencephalitis.
12. The method of claim 3 , wherein said disease is multiple sclerosis.
13. The method of claim 12 , wherein said multiple sclerosis is relapsing or remitting multiple sclerosis, primary progressive multiple sclerosis, or secondary progressive multiple sclerosis.